NCT00953576View on ClinicalTrials.gov

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 29, 2009

Primary Completion Date

April 11, 2013

Study Completion Date

April 11, 2013

Conditions
Prostate Cancer
Interventions
DRUG

ketoconazole

DRUG

hydrocortisone

DRUG

dutasteride

DRUG

lapatinib

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Prostate Cancer Foundation Clinical Research Consortium

NETWORK

collaborator

GlaxoSmithKline

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER